Grifols, S.A. (NASDAQ: GRFS) is a large market cap stock with a market cap of 22961.2. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 38.09, a forward P/E of 14.7 and EPS of 0.44. At a stock price of 16.79 (0.18%) it has a dividend yield of 3.10%.
EPS growth for the last five years have been 39.67%, more recently this last year it has grown by 3.00%. The next year growth is going to be about 10.70% and more long-term 15.00% after five years. EPS growth quarter over quarter is -2.50%. Sales growth for the past five years have been *TBA and sales growth quarter over quarter is 5.60%.
For performance, Grifols, S.A. the past week has seen a gain of -1.87%. For the last month performance for Grifols, S.A. is 6.21%. While the last quarter is 8.87% and half year, 13.40%. Finally for the year, performance is 6.49%.
The 52-week high for Grifols, S.A., is at -5.00%, and for the 52-week low it comes to a value of 20.46%. The 20-day simple moving average is 5.11% and 6.25% for the 200-day simple moving average.
Volatility for the week is at 1.03%, and for the month it is 1.90%. Grifols, S.A., has a target price of 15.
In terms of debt, long term debt/equity is *TBA, and for total debt/equity Grifols, S.A. has *TBA. The gross margin is *TBA, while operating margin is *TBA, the profit margin is *TBA. The current ratio is *TBA and the quick ratio is *TBA.
Insider ownership is at *TBA, with instituitional ownership at *TBA. Grifols, S.A. has a payout ratio of *TBA. With the total shares outstanding coming to 1370. The shares float is 1100, with the float short at 0.12%, with short ratio coming to 1.06.
In terms of returns, the return on assets see Grifols, S.A., get *TBA, with its returns on investment at *TBA. Return on equity is *TBA. So will the investors see the target price of 15, reached soon?
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.